Work Files Saved Searches
   My Account                                                  Search:   Quick/Number   Boolean   Advanced   Derwent    Help   


 The Delphion Integrated View

  Buy Now:   Buy PDF- 9pp  PDF  |   File History  |   Other choices   
  Tools:  Citation Link  |  Add to Work File:    
  View:  Expand Details   |  INPADOC   |  Jump to: 
  Go to:  Derwent  
 Email this to a friend  Email this to a friend 
       
Title: US5460831: Targeted transfection nanoparticles
[ Derwent Title ]


Country: US United States of America

View Images High
Resolution

 Low
 Resolution

 
9 pages

 
Inventor: Kossovsky, Nir; Los Angeles, CA
Hnatyszyn, H. James; Los Angeles, CA
Gelman, Andrew; Los Angeles, CA

Assignee: The Regents of the University of California, Oakland, CA
other patents from UNIVERSITY OF CALIFORNIA, THE REGENTS OF (599425) (approx. 4,840)
 News, Profiles, Stocks and More about this company

Published / Filed: 1995-10-24 / 1993-11-04

Application Number: US1993000147751

IPC Code: Advanced: A61K 9/00; A61K 9/127; A61K 9/51; A61K 38/28; A61K 38/40; A61K 38/42; A61K 38/48; A61K 39/12; A61K 39/21; A61K 47/26; A61K 47/48; A61K 48/00; A61L 31/10; C07K 14/05; C07K 14/16; C12N 11/14; C12N 15/87; A61K 38/00;
Core: A61K 38/41; A61K 38/43; A61L 31/08; C07K 14/005; C12N 11/00; more...
IPC-7: A61K 9/14;

ECLA Code: A61K9/00M5F; A61K9/00M5; A61K9/127; A61K9/51; A61K38/28; A61K38/40; A61K38/42; A61K38/48; A61K39/21; A61K47/26; A61K47/48W14B; A61K48/00; A61L31/10; C07K14/05; C07K14/16; C12N11/14; C12N15/87;

U.S. Class: Current: 424/493; 424/204.1; 424/490; 424/494; 424/498; 514/951; 514/970;
Original: 424/493; 424/490; 424/494; 424/498; 424/204.1; 514/951; 514/970;

Field of Search: 424/493,494,490,498

Priority Number:
1993-11-04  US1993000147751

Abstract:     A biologically active composition for use in gene therapy and other transfection procedures. The composition is composed of nanocrystalline core particles which are coated with a layer that is designed to allow attachment of transfection agents (DNA/RNA segments or antisense fragments) without denaturing them. The composition may further include an exterior targeting membrane which provides selective targeting of the transfection agents to specific cell receptors.

Attorney, Agent or Firm: Poms, Smith, Lande & Rose ;

Primary / Asst. Examiners: Page, Thurman K.; Spear, James M.

Maintenance Status: CC Certificate of Correction issued

INPADOC Legal Status: Show legal status actions          Buy Now: Family Legal Status Report

       
Related Applications:
Application Number Filed Patent Pub. Date  Title
US1993000000199 1993-01-04    1994-08-02  Human immunodeficiency virus decoy
US1991000690601 1991-04-24    1993-01-12  Viral decoy vaccine
US1990000542255 1990-06-22    1993-06-15  Biologically active composition having a nanocrystalline core


       
Parent Case:     This is a continuation-in-part of application Ser. No. 08/000,199, now U.S. Pat. No. 5,334,394 which was filed on Jan. 4, 1993 which is a continuation-in-part of Ser. No. 07/690,601 which was filed on Apr. 24, 1991, now U.S. Pat. No. 5,178,882 which is a continuation-in-part of application Ser. No. 07/542,255 which was filed on Jun. 22, 1990, now U.S. Pat. No. 5,219,577.

Designated Country: BB BG BR BY CZ FI HU KP KR KZ LK LV MG MN MW NO NZ OA PL RO  BE CH FR GB GR IT LI LU MC NL 

Family: Show 58 known family members

First Claim:
Show all 16 claims
What is claimed is:     1. A composition of matter comprising:
  • a biodegradable core particle having a diameter of less than about 1000 nanometers wherein said core particle comprises a biodegradable ceramic or polymer;
  • a coating comprising a substance that provides a threshold surface energy to said core particle which is sufficient to bind transfection agents without denaturing said agents, said substance covering at least a part of the surface of said core particle and wherein said substance is selected from the group consisting of carbohydrates, citrate, fumarate, succinate, isocitrate, oxalacetate, realate, pyridoxyl-5-pyrophosphate, thiamine pyrophosphate, uridine-diphosphate-glucose, glucose-1-phosphate, adenosine and nicotinamide-adenine-diphosphate;
  • at least one transfection active agent bound to said coated core particle wherein said transfection agent bound to said coated core particle is not denatured.


Background / Summary: Show background / summary

Drawing Descriptions: Show drawing descriptions

Description: Show description

Forward References: Show 102 U.S. patent(s) that reference this one

       
U.S. References: Go to Result Set: All U.S. references   |  Forward references (102)   |   Backward references (4)   |   Citation Link

Buy
PDF
Patent  Pub.Date  Inventor Assignee   Title
Buy PDF- 5pp US4501726  1985-02 Schroder et al.   Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
Buy PDF- 13pp US4904479  1990-02 Illum  Danbiosyst UK Limited Drug delivery system
Buy PDF- 9pp US5178882  1993-01 Kossovsky et al.  The Regents of the University of California Viral decoy vaccine
Buy PDF- 8pp US5219577  1993-06 Kossovsky et al.  The Regents of the University of California Biologically active composition having a nanocrystalline core
       
Foreign References: None

Other Abstract Info: CHEMABS 116(11)104322M CHEMABS 124(04)037703M CHEMABS 120(26)331094Q CHEMABS 123(08)093296X CHEMABS 123(16)208983P CHEMABS 124(01)007065N CHEMABS 124(04)037703M CHEMABS 124(06)066600F CHEMABS 124(06)066679P DERABS C1992-010276 DERABS C1994-134687 DERABS C1994-248851 DERABS C1994-248855 DERABS C1995-240364

Inquire Regarding Licensing

Powered by Verity


Plaques from Patent Awards      Gallery of Obscure PatentsNominate this for the Gallery...

Thomson Reuters Copyright © 1997-2010 Thomson Reuters 
Subscriptions  |  Web Seminars  |  Privacy  |  Terms & Conditions  |  Site Map  |  Contact Us  |  Help